Aditya Bardia

Aditya Bardia, MD, MPH, FASCO, is Professor of Medicine in the Division of Hematology/Oncology at the David Geffen School of Medicine at UCLA. He currently serves as Program Director of Breast Medical Oncology and Director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center.

Bardia earned his MPH degree in Epidemiology from the College of Public Health at the University of Iowa in 2004 and his MD degree in Medical Oncology from Johns Hopkins Kimmel Cancer Center in 2011, where he was a Clinical Fellow (2008–2011). Prior to joining UCLA, he was Director of Breast Cancer Research at Mass General Cancer Center (2021–2023), and was faculty at Harvard Medical School (2011–2023), where he also served as Associate Professor in Medicine (2021–2023). He joined the UCLA faculty as Professor in 2024. 

Bardia is an internationally renowned breast oncologist known for his pioneering clinical and translational research in the field of cancer therapeutics, particularly antibody drug conjugates. He is the principal investigator of several clinical trials investigating precision therapeutics, and has led the clinical development of novel therapies including sacituzumab govitecan (IMMU-132), the first ADC approved for patients with metastatic TNBC, and elacestrant, the first oral SERD approved for patients with metastatic HR+ breast cancer. He has also led the clinical development of blood-based biomarkers, such as CTCs and ctDNA, as "liquid biopsy" for identification of novel targets, therapy selection, monitoring and understanding resistance to guide therapeutic development. Beyond his leading-edge research, Bardia is highly regarded among peers as an excellent mentor and strong advocate for academic trainees and junior faculty members.

Bardia has been extensively honored for his work as a physician-scientist, including the Distinguished Researcher Award from the Massachusetts Society of Clinical Oncology (2022), the Young Investigator Award (2010) and multiple Merit awards (2010 and 2011) from ASCO, and the Outstanding Research Award from the Mayo Clinic (2007). He was also awarded the Douglas Family Foundation Prize for Excellence in Oncology Research by faculty at MGH (in 2014, 2016 and 2020, the K12 Paul Calabresi Award for Clinical Oncology from Dana Farber/Harvard Cancer Center in 2013, and world’s most influential/highly cited researcher in 2023, 2024 and 2025.